Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.

J Acquir Immune Defic Syndr

*Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Laboratory of Immunoregulation, NIAID, NIH, Baltimore, MD; ‡Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC; §Vaccine and Infectious Disease Science Division, Fred Hutchinson Cancer Research Institute, Seattle, WA; ‖Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; ¶Genomics Unit, Research Technologies Section, Rocky Mountain Laboratories, DIR, NIAID, NIH, Hamilton, MT; #Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; **Science Facilitation Department, FHI360, Washington, DC; ††Science Facilitation Department, FHI360, Durham, NC; ‡‡College of Medicine-Johns Hopkins Project, Blantyre, Malawi; §§UNC Project, Lilongwe, Malawi; ‖‖Department of Medicine, University of Zimbabwe, Harare, Zimbabwe; ¶¶HIV Research Branch, Center for Global Health, Kenya Medical Research Institute (KEMRI)-Centers for Disease Control (CDC), Kisumu, Kenya; ##BHHRL & Clinical Trials Unit, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; ***Soweto HPTN CRS, Chris Hani Baragwanath Hospital, Soweto, South Africa; †††YRGCARE Medical Centre, Chennai, India; ‡‡‡Center for AIDS and STDs, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; §§§Hospital Nossa Senhora da Conceição, Serviço de Infectologia, Porto Alegre, Brazil; ‖‖‖Hospital Geral de Nova Iguaçu and Laboratorio de AIDS e Imunologia Molecular (IOC/Fiocruz), Rio de Janeiro, Brazil; ¶¶¶Instituto Nacional de Infectologia Evandro Chagas-INI-Fiocruz, Rio de Janeiro, Brazil; ###Fenway Health and Infectious Disease Division, The Fenway Institute, Boston, MA; ****Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA; ††††Vaccine and Infectious Disease Division and Public Health Science Division, Fred Hutchinson Cancer Research Institute, Seattle, WA; ‡‡‡‡Department of Biostatistics, University of Washington, Seattle, WA; and §§§§Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Published: January 2017

HIV Prevention Trials Network 052 demonstrated that antiretroviral therapy (ART) prevents HIV transmission in serodiscordant couples. HIV from index-partner pairs was analyzed to determine the genetic linkage status of partner infections. Forty-six infections were classified as linked, indicating that the index was the likely source of the partner's infection. Lack of viral suppression and higher index viral load were associated with linked infection. Eight linked infections were diagnosed after the index started ART: 4 near the time of ART initiation and 4 after ART failure. Linked infections were not observed when the index participant was stably suppressed on ART.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140698PMC
http://dx.doi.org/10.1097/QAI.0000000000001158DOI Listing

Publication Analysis

Top Keywords

partner infections
8
hiv prevention
8
prevention trials
8
trials network
8
network 052
8
linked infections
8
infections
5
art
5
treatment prevention
4
prevention characterization
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!